Working… Menu

Egcg, a dyrk1a Inhibitor as Therapeutic Tool for Reversing Cognitive Deficits in Down Syndrome Individuals.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01394796
Recruitment Status : Completed
First Posted : July 14, 2011
Last Update Posted : March 13, 2013
Information provided by:
Parc de Salut Mar

Results Submitted - Not Posted on
Results information has been submitted to by the sponsor or investigator, but is not yet publicly available (or "posted") on The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
Recruitment Status : Completed
Actual Primary Completion Date : February 2011
Actual Study Completion Date : February 2011
Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 February 9, 2016
March 9, 2016
2 March 18, 2016
April 20, 2016
3 February 9, 2017
March 28, 2017
4 May 8, 2019
May 30, 2019
5 July 29, 2019
August 19, 2019